10058-F4: Targeted c-Myc-Max Dimerization Inhibitor Insights

Executive Summary: 10058-F4 is a cell-permeable small-molecule inhibitor that selectively disrupts c-Myc/Max heterodimer formation, impeding c-Myc's function as a transcription factor (APExBIO product specification). This action leads to cell cycle arrest and apoptosis, notably in acute myeloid leukemia (AML) and prostate cancer models, as demonstrated through both in vitro and in vivo studies (Stern et al., 2024). 10058-F4’s mechanism is validated by decreased c-Myc mRNA, increased mitochondrial apoptotic signaling, and tumor suppression metrics. The compound's solubility and storage parameters are well-defined, supporting reproducibility in apoptosis assay workflows. Although highly targeted, users must consider solubility limits and specificity in experimental design.

Biological Rationale

c-Myc is a proto-oncogene and transcription factor critical for cell proliferation, metabolism, and stem cell maintenance. Its aberrant activation is a hallmark of many human cancers, including acute myeloid leukemia and prostate cancer (Stern et al., 2024). c-Myc exerts its function primarily through heterodimerization with Max, enabling DNA binding and transcriptional activation of downstream targets such as PGC-1β. Disruption of c-Myc-Max dimerization is thus a rational strategy for targeted cancer intervention. The APEX2/APE2 DNA repair enzyme, recently implicated in telomerase (TERT) gene regulation, further underscores the interplay between oncogenic transcription factors and genome maintenance in stem cells and cancer biology.

Mechanism of Action of 10058-F4 C-Myc-Max Dimerization Inhibitor

10058-F4, chemically designated as (5E)-5-[(4-ethylphenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one, is a selective inhibitor that binds to the c-Myc bHLHZip domain, preventing its heterodimerization with Max (APExBIO). This blockade precludes c-Myc/Max complexes from binding E-box sequences in DNA, thereby inhibiting transcriptional activation of genes involved in cell growth and survival. As a result, 10058-F4 treatment leads to a reduction in c-Myc mRNA and protein levels, cell cycle arrest in G1, and activation of mitochondrial apoptosis pathways, including downregulation of Bcl-2, upregulation of Bax, and cytochrome C release. These effects have been validated in AML cell lines (HL-60, U937, NB-4) and human prostate cancer xenografts (DU145, PC-3), with dose-dependent responses observed in both in vitro and in vivo systems.

Evidence & Benchmarks

• 10058-F4 specifically disrupts c-Myc-Max dimerization, reducing c-Myc-driven transcription in AML and prostate cancer cells (APExBIO).
• In vitro, 10058-F4 treatment of AML cell lines (HL-60, U937, NB-4) induces G1 cell cycle arrest and mitochondrial apoptosis, as evidenced by Bcl-2 downregulation and Bax upregulation (Stern et al., 2024).
• In SCID mice bearing prostate cancer xenografts (DU145, PC-3), daily intravenous administration of 20–30 mg/kg 10058-F4 for two weeks results in significant tumor control, with efficacy varying by model (APExBIO).
• 10058-F4 demonstrates high solubility in DMSO (≥24.9 mg/mL) and ethanol (≥2.64 mg/mL), but is insoluble in water, necessitating careful preparation for biological assays (APExBIO).
• Recent studies reveal a mechanistic bridge between c-Myc, telomerase (TERT) expression, and DNA repair via APEX2, highlighting 10058-F4 as a tool for dissecting oncogenic transcriptional regulation (Stern et al., 2024).

For comparative context, see the article "10058-F4: Redefining c-Myc-Max Inhibition for Apoptosis and Telomerase Research", which uniquely integrates mitochondrial apoptosis and telomerase insights; the present article further clarifies protocol limits and workflow integration for oncology labs. Similarly, "10058-F4 C-Myc-Max Dimerization Inhibitor: Shaping Cancer Assay Innovation" discusses assay development, while this dossier emphasizes evidence benchmarks and solubility constraints.

Applications, Limits & Misconceptions

10058-F4 is valuable for acute myeloid leukemia research, apoptosis assays, and in vivo modeling of c-Myc transcription factor inhibition. Its use is supported by reproducible benchmarks in both cell culture and xenograft systems. However, its specificity for c-Myc-Max interaction means it does not inhibit other bHLHZip transcription factors. 10058-F4 is not a pan-apoptosis inducer and must be used at concentrations that avoid off-target cytotoxicity. It is unsuitable for diagnostic or clinical use.

Common Pitfalls or Misconceptions

• Assuming water solubility: 10058-F4 is insoluble in water; use DMSO or ethanol for stock solutions (APExBIO).
• Misapplying to non-Myc-driven cancers: Efficacy is context-dependent and limited to models with c-Myc/Max dependency.
• Expecting permanent solution stability: Stock solutions should not be stored long-term; prepare fresh as needed.
• Overlooking apoptosis pathway specificity: Induction of apoptosis is via mitochondrial mechanisms, not universal cell death.
• Using for clinical or diagnostic purposes: 10058-F4 is strictly for research use, not for therapeutic or diagnostic application.

Workflow Integration & Parameters

• Stock solution preparation: Dissolve in DMSO at concentrations ≥12.5 mg/mL (optimal ≥24.9 mg/mL); warm to 37°C or sonicate for faster dissolution (APExBIO).
• Storage: Store dry powder and DMSO stock at -20°C for several months; avoid repeated freeze-thaw cycles.
• Working concentration: Typical in vitro assays use final concentrations of 10–100 μM, with DMSO content ≤0.1% (v/v) in cell culture media.
• In vivo dosing: For SCID mouse prostate cancer xenografts, 20–30 mg/kg/day intravenously for up to 14 days has achieved tumor growth inhibition.
• Apoptosis assay integration: Use AML cell lines (HL-60, U937, NB-4) to measure mitochondrial pathway markers (Bcl-2, Bax, cytochrome C release) post-treatment.
• Shipping notes: Compound is shipped on blue ice; inspect for physical integrity upon arrival.

Conclusion & Outlook

10058-F4 is a verified, research-grade c-Myc-Max dimerization inhibitor that enables detailed study of oncogenic transcriptional regulation, apoptosis mechanisms, and tumor suppression (APExBIO). The compound supports mechanistic studies into the interplay between c-Myc, telomerase (TERT), and DNA repair in cancer and stem cell contexts, as evidenced by recent findings on APEX2’s regulatory roles (Stern et al., 2024). For oncology researchers, 10058-F4 offers precise workflow integration with clear solubility and handling parameters, but its application should remain restricted to research domains with validated c-Myc-Max dependency.